PD-L1 and CD58 co-regulated by CMTM6 play yin and yang to shape anti-tumor immunity

Hirohito Yamaguchi; Mien-Chie Hung

doi:10.1016/j.ccell.2023.08.009

PD-L1 and CD58 co-regulated by CMTM6 play yin and yang to shape anti-tumor immunity

Cancer Cell. 2023 Oct 9;41(10):1701-1704. doi: 10.1016/j.ccell.2023.08.009. Epub 2023 Sep 7.

Authors

Hirohito Yamaguchi¹, Mien-Chie Hung²

Affiliations

¹ Graduate Institute of Biomedical Sciences and Institute of Biochemistry and Molecular Biology, China Medical University, Taichung City 406040, Taiwan; Center for Molecular Medicine, China Medical University Hospital, Taichung City 40402, Taiwan; Cancer Biology and Precision Therapeutics Center and Research Center for Cancer Biology, China Medical University, Taichung City 40402, Taiwan.
² Graduate Institute of Biomedical Sciences and Institute of Biochemistry and Molecular Biology, China Medical University, Taichung City 406040, Taiwan; Center for Molecular Medicine, China Medical University Hospital, Taichung City 40402, Taiwan; Cancer Biology and Precision Therapeutics Center and Research Center for Cancer Biology, China Medical University, Taichung City 40402, Taiwan. Electronic address: mhung@cmu.edu.tw.

PMID: 37683640
DOI: 10.1016/j.ccell.2023.08.009

Abstract

The CD58-CD2 axis regulates T cell-mediated cancer immunity, but little is known about the regulation of CD58. In two recent papers pubished in Cancer Cell, Miao et al. and Ho et al. define a mechanism of CD58 regulation by CMTM6 and show an unexpected yin-yang link between PD-L1 and CD58.